FIELD: biotechnology.
SUBSTANCE: invention relates to glycosidic derivatives of 1,2-dithiole-3-thione or 1,2-dithiol-3-one of formula 1 , where R1=S or O; R2 is a residue of per-O-acetyl D-glucose, per-O-acetyl D-galactose, per-O-acetyl D-mannose, per-O-acetyl D-xylose, per-O-acetyl L-arabinose, per-O-acetyl-D-maltose or D-glucose, which can be used against cancerous diseases.
EFFECT: new bioactive compounds with cancerous preventive action and pharmaceutical products based on them are proposed, which display the cancerous preventive effect in non-cytotoxic concentrations.
2 cl, 4 ex, 5 tbl
Title | Year | Author | Number |
---|---|---|---|
AGENT PREVENTING MAMMAL NORMAL CELL TRANSFORMATION IN MALIGNANT CELLS | 2010 |
|
RU2429840C1 |
AGENT PREVENTING MAMMAL NORMAL CELL TRANSFORMATION IN MALIGNANT CELLS | 2010 |
|
RU2429839C1 |
THERAPEUTIC QUINONES | 2005 |
|
RU2411229C2 |
PHARMACEUTICAL COMPOSITION CONTAINING 1,2-DITHIOL-THIONE DERIVATIVE FOR PREVENTING OR TREATING DISEASES MEDIATED BY HIGH LXR-ALPHA EXPRESSION | 2009 |
|
RU2491065C2 |
PHARMACEUTICAL COMPOSITION, INCLUDING TRICYCLIC SULFUR-CONTAINING 1,2-DIHYDROQUINOLINE DERIVATIVE FOR INHIBITION OF REPLICATION OF BETA CORONAVIRUSES, INCLUDING SARS-CoV-2, AND METHOD OF ITS USE | 2021 |
|
RU2814434C1 |
METHOD OF PRODUCING A TRICYCLIC SULFUR-CONTAINING DERIVATIVE OF 1,2-DIHYDROQUINOLINE FOR INHIBITING REPLICATION OF BETA-CORONAVIRUSES, INCLUDING SARS-CoV-2 | 2021 |
|
RU2819783C1 |
MEDICATION INFLUENCING ACTIVITY OF SOME NUCLEAR TRANSCRIPTION FACTORS | 2011 |
|
RU2457840C1 |
APPLICATION OF A TRICYCLIC SULPHUR-CONTAINING DERIVATIVE OF 1,2-DIHYDROQUINOLINE FOR INHIBITING THE REPLICATION OF BETACORONAVIRUSES, INCLUDING SARS-COV-2 | 2021 |
|
RU2780247C1 |
AGENT STIMULATING HUMAN LEUKAEMIA CELL APOPTOSIS (VERSIONS) | 2007 |
|
RU2372919C2 |
ANTICANCER DRUG | 2009 |
|
RU2414920C1 |
Authors
Dates
2014-11-27—Published
2013-09-24—Filed